Clinical Outcome Differences in the Treatment of Impending Versus Completed Pathological Long-Bone Fractures
- PMID: 34851323
- DOI: 10.2106/JBJS.21.00711
Clinical Outcome Differences in the Treatment of Impending Versus Completed Pathological Long-Bone Fractures
Abstract
Background: The outcome differences following surgery for an impending versus a completed pathological fracture have not been clearly defined. The purpose of the present study was to assess differences in outcomes following the surgical treatment of impending versus completed pathological fractures in patients with long-bone metastases in terms of (1) 90-day and 1-year survival and (2) intraoperative blood loss, perioperative blood transfusion, anesthesia time, duration of hospitalization, 30-day postoperative systemic complications, and reoperations.
Methods: We retrospectively performed a matched cohort study utilizing a database of 1,064 patients who had undergone operative treatment for 462 impending and 602 completed metastatic long-bone fractures. After matching on 22 variables, including primary tumor, visceral metastases, and surgical treatment, 270 impending pathological fractures were matched to 270 completed pathological fractures. The primary outcome was assessed with the Cox proportional hazard model. The secondary outcomes were assessed with the McNemar test and the Wilcoxon signed-rank test.
Results: The 90-day survival rate did not differ between the groups (HR, 1.13 [95% CI, 0.81 to 1.56]; p = 0.48), but the 1-year survival rate was worse for completed pathological fractures (46% versus 38%) (HR, 1.28 [95% CI, 1.02 to 1.61]; p = 0.03). With regard to secondary outcomes, completed pathological fractures were associated with higher intraoperative estimated blood loss (p = 0.03), a higher rate of perioperative blood transfusions (p = 0.01), longer anesthesia time (p = 0.04), and more reoperations (OR, 2.50 [95% CI, 1.92 to 7.86]; p = 0.03); no differences were found in terms of the rate of 30-day postoperative complications or the duration of hospitalization.
Conclusions: Patients undergoing surgery for impending pathological fractures had lower 1-year mortality rates and better secondary outcomes as compared with patients undergoing surgery for completed pathological fractures when accounting for 22 covariates through propensity matching. Patients with an impending pathological fracture appear to benefit from prophylactic stabilization as stabilizing a completed pathological fracture seems to be associated with increased mortality, blood loss, rate of blood transfusions, duration of surgery, and reoperation risk.
Level of evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
Copyright © 2021 by The Journal of Bone and Joint Surgery, Incorporated.
Conflict of interest statement
Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJS/G816).
Similar articles
-
Are Allogeneic Blood Transfusions Associated With Decreased Survival After Surgery for Long-bone Metastatic Fractures?Clin Orthop Relat Res. 2015 Jul;473(7):2343-51. doi: 10.1007/s11999-015-4167-3. Epub 2015 Jan 31. Clin Orthop Relat Res. 2015. PMID: 25637400 Free PMC article.
-
Hospital-related healthcare expenditure of impending versus completed pathological femur fractures: a propensity score matched study of 265 patients.Acta Orthop. 2025 May 27;96:401-410. doi: 10.2340/17453674.2025.43479. Acta Orthop. 2025. PMID: 40460269 Free PMC article.
-
What Factors Are Associated With Local Metastatic Lesion Progression After Intramedullary Nail Stabilization?Clin Orthop Relat Res. 2022 May 1;480(5):932-945. doi: 10.1097/CORR.0000000000002104. Epub 2021 Dec 28. Clin Orthop Relat Res. 2022. PMID: 34962492 Free PMC article.
-
Surgical stabilization of pathological neoplastic fractures.Curr Probl Cancer. 1986 Mar;10(3):117-68. doi: 10.1016/s0147-0272(86)80005-8. Curr Probl Cancer. 1986. PMID: 3514130 Review.
-
Orthopedic surgical management of skeletal complications of malignancy.Cancer. 1997 Oct 15;80(8 Suppl):1614-27. doi: 10.1002/(sici)1097-0142(19971015)80:8+<1614::aid-cncr12>3.3.co;2-0. Cancer. 1997. PMID: 9362429 Review.
Cited by
-
Prevalence of primary malignant tumours, rates of pathological fracture, and mortality in the setting of metastatic bone disease.Bone Jt Open. 2023 Jun 5;4(6):424-431. doi: 10.1302/2633-1462.46.BJO-2023-0042.R1. Bone Jt Open. 2023. PMID: 37272304 Free PMC article.
-
CORR Insights®: What Factors Are Associated With Implant Revision in the Treatment of Pathologic Subtrochanteric Femur Fractures?Clin Orthop Relat Res. 2025 Mar 1;483(3):485-487. doi: 10.1097/CORR.0000000000003370. Epub 2024 Dec 31. Clin Orthop Relat Res. 2025. PMID: 39787403 No abstract available.
-
Treating pathological metastatic fractures of the humerus by compound osteosynthesis: a retrospective cohort study.JSES Int. 2024 Jan 11;8(3):446-450. doi: 10.1016/j.jseint.2023.12.002. eCollection 2024 May. JSES Int. 2024. PMID: 38707561 Free PMC article.
-
Risk Factors for Early Postoperative Morbidity and Mortality following Extremity Metastatic Pathologic or Impending Fracture Fixation.Int J Surg Oncol. 2024 Sep 12;2024:3565134. doi: 10.1155/2024/3565134. eCollection 2024. Int J Surg Oncol. 2024. PMID: 39301148 Free PMC article.
-
Intervention for impending pathological fractures at proximal femur is associated with lower mortality rates in patients with intermediate-to-high risk according to the Katagiri-New score.BMC Musculoskelet Disord. 2024 Oct 22;25(1):836. doi: 10.1186/s12891-024-07838-8. BMC Musculoskelet Disord. 2024. PMID: 39438850 Free PMC article.
References
-
- Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001 Jun;27(3):165-76.
-
- Damron TA, Mann KA. Fracture risk assessment and clinical decision making for patients with metastatic bone disease. J Orthop Res. 2020 Jun;38(6):1175-90.
-
- Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-9s.
-
- von Moos R, Body JJ, Egerdie B, Stopeck A, Brown J, Fallowfield L, Patrick DL, Cleeland C, Damyanov D, Palazzo FS, Marx G, Zhou Y, Braun A, Balakumaran A, Qian Y. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Support Care Cancer. 2016 Mar;24(3):1327-37.
-
- Aneja A, Jiang JJ, Cohen-Rosenblum A, Luu HL, Peabody TD, Attar S, Luo TD, Haydon RC. Thromboembolic Disease in Patients with Metastatic Femoral Lesions: A Comparison Between Prophylactic Fixation and Fracture Fixation. J Bone Joint Surg Am. 2017 Feb 15;99(4):315-23.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials